Market Place
Sourcing Support
Entrada Therapeutics Reports Q3 2024 Financial Results
05 Nov 2024 //
GLOBENEWSWIRE
Entrada Presents Duchenne Data At World Muscle Society
09 Oct 2024 //
GLOBENEWSWIRE
Entrada Therapeutics Promotes Natarajan Sethuraman to President R&D
24 Sep 2024 //
GLOBENEWSWIRE
Entrada Therapeutics Announces Recipients Of Second Annual DREAMS Grant
06 Sep 2024 //
GLOBENEWSWIRE
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
13 Aug 2024 //
GLOBENEWSWIRE
Entrada reports positive Phase 1 ENTR-601-44-101 Trial data for DMD.
24 Jun 2024 //
GLOBENEWSWIRE
Entrada Therapeutics Announces $100 Million Registered Direct Offering
24 Jun 2024 //
GLOBENEWSWIRE
Entrada To Present At Goldman Sachs Healthcare Conference
03 Jun 2024 //
GLOBENEWSWIRE
Entrada Therapeutics To Present At Wainwright BioConnect
16 May 2024 //
GLOBENEWSWIRE
Entrada Therapeutics Reports First Quarter 2024 Financial Results
07 May 2024 //
GLOBENEWSWIRE
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
13 Mar 2024 //
GLOBENEWSWIRE
Entrada Therapeutics to Present at Upcoming Investor Conferences
07 Feb 2024 //
GLOBENEWSWIRE
Entrada Therapeutics Promotes Nathan J. Dowden to President
03 Jan 2024 //
GLOBENEWSWIRE
Entrada Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
22 Nov 2023 //
GLOBENEWSWIRE
FDA rebuffs Entrada`s attempt to get DMD clinical hold lifted
22 Nov 2023 //
FIERCE BIOTECH
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Entrada Therapeutics to Present at Upcoming Investor Conferences
12 Oct 2023 //
GLOBENEWSWIRE
Entrada Announces First Participant Dosed in its Phase 1 Trial of ENTR-601-44
21 Sep 2023 //
GLOBENEWSWIRE
Entrada Awards Funding to Non-Profit Organizations Advancing Diversity
07 Sep 2023 //
GLOBENEWSWIRE
Entrada Therapeutics to Present at Upcoming Investor Conferences
29 Aug 2023 //
GLOBENEWSWIRE
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
10 Aug 2023 //
GLOBENEWSWIRE
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Entrada Receives Authorization in UK to Initiate Phase 1 Trial of ENTR-601-44
01 Aug 2023 //
GLOBENEWSWIRE
Entrada to Present at Goldman Sachs 44th Annual Global Healthcare Conference
06 Jun 2023 //
GLOBENEWSWIRE
Entrada Therapeutics Reports First Quarter 2023 Financial Results
10 May 2023 //
GLOBENEWSWIRE
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
04 Apr 2023 //
GLOBENEWSWIRE
Entrada to Participate in Guggenheim Genomic Medicines & Rare Disease Conference
29 Mar 2023 //
GLOBENEWSWIRE
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
06 Mar 2023 //
GLOBENEWSWIRE
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
27 Feb 2023 //
GLOBENEWSWIRE
Entrada Closes Agreement with Vertex to Discover Endosomal Escape Vehicle
09 Feb 2023 //
GLOBENEWSWIRE
Entrada Announces ENTR-601-45 for the Treatment of Duchenne Muscular Dystrophy
09 Jan 2023 //
GLOBENEWSWIRE
FDA halts planned trial of Entrada Duchenne drug
21 Dec 2022 //
BIOPHARMADIVE
FDA Places Clinical Hold on Entrada’s IND for Duchenne Muscular Dystrophy
20 Dec 2022 //
BIOSPACE
Vertex Pursues Myotonic Dystrophy for potential $485 million Entrada Deal
09 Dec 2022 //
BIOSPACE
Entrada to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
22 Nov 2022 //
GLOBENEWSWIRE
Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Investment
30 Aug 2022 //
GLOBENEWSWIRE
Entrada Therapeutics Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
GLOBENEWSWIRE
Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer
19 Jul 2022 //
GLOBENEWSWIRE
Entrada Therapeutics to Present at William Blair Biotech Focus Conference
06 Jul 2022 //
GLOBENEWSWIRE
Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
Entrada Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Entrada Therapeutics Presents New Data in EEV Therapeutics at TIDES USA 2022
11 May 2022 //
GLOBENEWSWIRE
Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference
10 May 2022 //
GLOBENEWSWIRE
Entrada Tx Reports Q4 and FY 2021 Financial Results
15 Mar 2022 //
GLOBENEWSWIRE
Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference
23 Feb 2022 //
GLOBENEWSWIRE
Spooky SPAC season and a $180M Entrada onto Wall Street
30 Oct 2021 //
MARKETWATCH
Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering
28 Oct 2021 //
GLOBENEWSWIRE
Rare disease biotech Entrada Therapeutics files for a $100 million IPO
25 Oct 2021 //
RENAISSANCECAPITAL
IPO floodgates open up after summer lull as five more biotechs file for Nasdaq
13 Oct 2021 //
ENDPTS
